UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at http://www.ucl.ac.uk/finance/research/post_award/post_award_contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
The Role of Prostaglandin E2 in Critical Illness-Induced Immune Dysfunction
  • Publication Type:
    Thesis/Dissertation
  • Authors:
    Fullerton JN
  • Date awarded:
    2016
  • Supervisors:
    Gilroy DW,Singer M
  • Status:
    Unpublished
  • Awarding institution:
    University College London
  • Date Submitted:
    01/01/2015
  • Keywords:
    Cyclooxygenase, Inflammation, Monocytes, Non-steroidal anti-inflammatory drugs, Tumour necrosis factor-alpha, Intensive care
  • Addresses:
    Dr James Fullerton
    University College London
    Centre for Clinical Pharmacology, Division of Medicine
    Rayne Institute, 5 University Street
    London
    WC1E 6JF
    United Kingdom
  • Notes:
    The appendices have not been included in the page count
Abstract
Dysregulation of the inflammatory profile in magnitude or duration following severe infectious or sterile insults including sepsis, burn and trauma is associated with a period of immunoparalysis, the acquisition of hospital acquired-infections and an associated increase in mortality. Prostaglandin E2 (PGE2), a cyclooxygenase (COX)-derived eicosanoid classically regarded as pro-inflammatory, regulates multiple aspects of the immune response and has been ascribed a causal role in immunoparalysis during alternate disease states. Systematic review of the clinical literature relating COX-inhibiting non-steroidal anti-inflammatory drugs (NSAIDs) use with either susceptibility to or outcome from acute infection revealed epidemiological evidence of benefit from NSAID administration during severe inflammatory states (sepsis), but not minor infection, providing a rationale for investigation of a mechanistic contribution to critical illness-induced immune dysfunction (CIIID). PGE2, at pathophysiologically relevant concentrations (IC50 317pg/mL, 95% CI 105 – 959pg/mL), suppressed ex vivo whole blood (WB) cytokine secretion: a validated measure of clinically relevant immune dysfunction. EP4 receptor-mediated increase in intracellular cyclic adenosine monophosphate (cAMP) was determined as the principal pathway, antagonism of which afforded an alternate immunorestorative strategy to established immunoadjuvant agents (interferon-γ and granulocyte-macrophage colony stimulating factor). A complementary in vitro bioassay of PGE2-mediated monocyte deactivation employing 1α, 25 dihydroxycholecalciferol differentiated (vitamin D3, 10ng/ml) Mono Mac 6 (MM6), a human cell line, mirrored this response. Pre-clinical evaluation of an association between PGE2 release during the systemic inflammatory response syndrome (SIRS) and subsequent immunoparalysis using the human intravenous endotoxin model (2ng/kg), however neither confirmed this link, nor refuted it, failing to replicate key immunological features of CIIID (sustained reduction in monocyte HLA-DR expression, WB cytokine secretion and absolute lymphocyte count). Mass spectroscopic analysis of plasma revealed significant elevation of COX-derived PGF2α, thromboxane A2 and PGE2, the latter peaking at 3hours, 7.8x higher than baseline values (10pg/mL compared to 1.3pg/mL). These did not suppress MM6 cytokine release. Compelling arguments suggest PGE2 contributes to CIIID. Alternative or adapted techniques will be required to determine the validity of this premise, potentially identifying a novel therapeutic immunorestorative strategy in the critically ill.
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers
Author
Div of Medicine
Editor
Metabolism & Experi Therapeutics
Editor
Internal Medicine
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by